Literature DB >> 22547363

[Arterial Hypertension - when are which combination therapies useful?].

Roman Brenner1, Stefano F Rimoldi, Emrush Rexhaj, Yves Allemann.   

Abstract

Arterial hypertension is a widely prevalent risk factor for cardiovascular diseases with well documented harmful effects on the heart and the vascular system. Despite a broad antihypertensive drug armamentarium control of hypertension is worldwide suboptimal. Daily practice as well as large intervention trials show that single-drug therapy often fails to adequately control blood pressure (BP). Therefore, the early introduction of a combination therapy may lead to a better and more rapid BP lowering effect, particularly in patients with more than stage I hypertension or in patients with mild hypertension and high cardiovascular risk. In addition, side effects of an antihypertensive drug can be prevented by a meaningful (low dose) combination with a second antihypertensive agent. Moreover, combination of antihypertensive drugs, especially if provided fixed, may substantially improve compliance. However, the choice of the drug combination primarily relates on the demographic features and co-morbidities of the patient. Although BP lowering is the main determinant of cardiovascular risk reduction in the treatment of hypertension, some antihypertensive drugs may exhibit protective effects beyond BP reduction that have to be considered when antihypertensive drugs are combined. In recent large intervention studies, the combination of an ACE inhibitor with a calcium channel blocker was especially advantageous in high risk hypertensive patients. The addition of a thiazide type diuretic to a blocker of the renin-angiotensin system is also sensible and popular with numerous available fixed combinations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22547363     DOI: 10.1024/0040-5930/a000290

Source DB:  PubMed          Journal:  Ther Umsch        ISSN: 0040-5930


  1 in total

1.  Analysis of treatment pathways for three chronic diseases using OMOP CDM.

Authors:  Xin Zhang; Li Wang; Shumei Miao; Hua Xu; Yuechuchu Yin; Yueshi Zhu; Zuolei Dai; Tao Shan; Shenqi Jing; Jian Wang; Xiaoliang Zhang; Zhongqiu Huang; Zhongmin Wang; Jianjun Guo; Yun Liu
Journal:  J Med Syst       Date:  2018-11-13       Impact factor: 4.460

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.